We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Anavex Life Sciences Corporation | NASDAQ:AVXL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 1.47% | 3.44 | 1.80 | 6.35 | 3.48 | 3.37 | 3.40 | 949,972 | 05:00:07 |
ANAVEX LIFE SCIENCES CORP.
51 W. 52nd Street, 7th Floor
New York, NY 10019-6163
September 16, 2019
VIA EDGAR
United States Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Re: | Anavex Life Sciences Corp. | |
Form AW - Request for Withdrawal | ||
Amendment No. 4 to Registration Statement on Form S-3 | ||
File No. 333-207600 |
Ladies and Gentlemen:
Pursuant to Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), Anavex Life Sciences, Corp., a Nevada corporation (the “Company”), hereby requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal, effective as of the date hereof or at the earliest practicable date hereafter, of Amendment No. 4 its Registration Statement on Form S-3 (File No. 333-207600) (the “Amendment”), filed with the U.S. Securities and Exchange Commission on September 13, 2019.
The grounds for this application for withdrawal are that, subsequent to the filing of the Amendment, the Company determined that the Amendment had been improperly tagged as a pre-effective amendment, rather than a post-effective amendment. As discussed with the Staff, the Company requests withdrawal of the Amendment to permit the re-filing the Amendment properly tagged as a post-effective amendment.
No securities have been sold under the registration statement of which the Amendment is a part.
Please direct any questions or comments regarding this filing to Clayton Parker, Esq. at (305) 794-6293 of K&L Gates LLP, legal counsel to the Company.
Sincerely, | |
/s/ Christopher Missling, PhD | |
Christopher Missling, PhD Chief Executive Officer |
1 Year Anavex Life Sciences Chart |
1 Month Anavex Life Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions